西隴科學(002584.SZ):上半年淨利潤預增154.93%-258.49%
格隆匯7月8日丨西隴科學(002584.SZ)公佈2024年半年度業績預吿,報吿期歸屬於上市公司股東的淨利潤盈利3200萬元–4500萬元,比上年同期增長154.93%-258.49%;扣除非經常性損益後的淨利潤盈利3000萬元–4000萬元,比上年同期增長378.43%-537.91%;基本每股收益盈利0.05元/股–0.08元/股。
2024年1-6月份歸屬於上市公司股東的淨利潤同比上期增長,主要原因是報吿期內,化學試劑及專用化學品的市場需求上升,收入和利潤同比均有增加。此外,公司持續提升經營管理水平,進一步提升盈利水平和市場競爭力,多措並舉實現上半年業績同比增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.